Innowacje dla Przyszłości Non-profit Spółka z Ograniczoną Odpowiedzialnością (KRS 0000697236, NIP 8943114661) is a Polish company, headquartered in Wrocław, Dolnośląskie voivodeship. INNOWACJE DLA PRZYSZŁOŚCI NON-PROFIT operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since September 28, 2017.
Negative equity
Negative equity in 4 of 7 available reporting years.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Innowacje dla Przyszłości Non-profit
Identity
- Name
- Innowacje dla Przyszłości Non-profit Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- September 28, 2017
- Registry status as of
- December 3, 2025
- Latest entry
- April 7, 2025
- Founding act
- 26.09.2017R.
Articles of association history (3)
- September 26, 2017: 26.09.2017R.
- March 29, 2019: 29.03.2019R., NOTARIUSZ BARTOSZ MASTERNAK, KANCELARIA NOTARIALNA WE WROCŁAWIU, REP. A NR 6479/2019, UCHYLENIE CAŁEGO DOTYCHCZASOWEGO BRZMIENIA UMOWY SPÓŁKI I PRZYJĘCIE NOWEGO BRZMIENIA (§ 1-17) 14.08.2019R., NOTARIUSZ BARTOSZ MASTERNAK, KANCELARIA NOTARIALNA WE WROCŁAWIU, REP. A NR 18656/2019, SPROSTOWANO: § 5 UST. 1 UMOWY SPÓŁKI.
- November 8, 2021: 08.11.2021 R., NOTARIUSZ IWONA KALINOWSKA, KANCELARIA NOTARIALNA WE WROCŁAWIU RYNEK 7, REP. A NR 28534/2021, ZMIENIONO: §2 UST. 1 PKT 3, §2 UST. 2 PKT 3, §4 UST. 1 PKT 6; DODANO W §2 UST. 1 PKT 4 I 5, W §2 UST. 2 PKT 4-8, W §4 UST. 1 PKT 7-10.
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
Address and contact
- Address
- PL. SOLNY, 14, 3, 50-062, WROCŁAW, POLSKA
- Voivodeship
- DOLNOŚLĄSKIE
- District
- WROCŁAW
- INNOWACJE@FUNDACJASENSORIA.PL
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-25389-60367-BUTJI-27
- Coordinates
- 51.1100, 17.0319approx.
Risk and payment profile - Innowacje dla Przyszłości Non-profit
Credibility rating
28 / 100
Poor credibility
Insolvency risk
Moderate
Significant formal threat
Closure risk
35
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/9 yrs
Board changes
1
1/9 yrs
PKD changes
2
2/9 yrs
Name changes
1
1/9 yrs
Data from 9 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: E (28/100)
Trend: stable (+0.9 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2018–2024
Current: 0 PLN
Safe: 0 PLN
Operational status - Innowacje dla Przyszłości Non-profit
Founded
September 28, 2017
8 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WROCŁAW
DOLNOŚLĄSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
5.0 K PLN
Shareholders
1
shareholder
Board
1 person
Filed years
7 years
2018–2024 · profitable: 0/7
Registry entries
22
latest: April 7, 2025
Risk signals
Revenue
N/A
2024
Net profit
-5.6 K PLN
2024
Assets
668.9 K PLN
2024
Equity
3.3 K PLN
2024
Valuation
353.6 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Innowacje dla Przyszłości Non-profit.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
